Betamox LA 150 mg/ml Injekční suspenze Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

betamox la 150 mg/ml injekční suspenze

norbrook laboratories (ireland) limited - amoxicilin - injekční suspenze - 150mg/ml - peniciliny s rozšířeným spektrem - skot, ovce, prasata, psi, kočky

NORODINE 40/200 mg/ml Injekční roztok Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

norodine 40/200 mg/ml injekční roztok

norbrook laboratories (ireland) limited - solí a trimethoprim - injekční roztok - kombinace sulfonamidů a trimethoprimu, včetně. deriváty - koně, kočky, prasata, skot, psi

GYNO-PEVARYL 150MG Vaginální kulička Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

gyno-pevaryl 150mg vaginální kulička

trimb healthcare ab, stockholm array - 2186 ekonazol-nitrÁt - vaginální kulička - 150mg - ekonazol

GYNO-PEVARYL 50MG Vaginální kulička Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

gyno-pevaryl 50mg vaginální kulička

trimb healthcare ab, stockholm array - 2186 ekonazol-nitrÁt - vaginální kulička - 50mg - ekonazol

Stribild Evropská unie - čeština - EMA (European Medicines Agency)

stribild

gilead sciences ireland uc - elvitegravir, kobicistat, emtricitabin, tenofovir-disoproxil-fumarát - hiv infekce - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - léčbě viru lidské imunodeficience 1 (hiv-1) infekce u dospělých ve věku 18 let a nad kdo jsou neléčených antiretrovirotiky nebo infikovaných hiv 1 bez známých mutací spojených s rezistencí na kterékoliv ze tří antiretrovirotik obsažených v přípravku.

Panacur 250 mg Tableta Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

panacur 250 mg tableta

intervet international, b.v. - fenbendazol - tableta - 250mg - benzimidazoles a související látky - kočky, psi

Prezista Evropská unie - čeština - EMA (European Medicines Agency)

prezista

janssen-cilag international nv - darunavir - hiv infekce - antivirotika pro systémové použití - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Phelinun Evropská unie - čeština - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastická činidla - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

ABELCET LIPID COMPLEX 5MG/ML Koncentrát pro infuzní disperzi Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

abelcet lipid complex 5mg/ml koncentrát pro infuzní disperzi

teva pharmaceuticals cr, s.r.o., praha array - 76 amfotericin b - koncentrát pro infuzní disperzi - 5mg/ml - amfotericin b

CLINIMIX N14G30E Infuzní roztok Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

clinimix n14g30e infuzní roztok

baxter czech spol. s r.o., praha array - 829 leucin; 1117 fenylalanin; 2445 methionin; 851 lysin-hydrochlorid; 790 isoleucin; 1514 valin; 717 histidin; 1459 threonin; 1503 tryptofan; 27 alanin; 96 arginin; 55 glycin; 4147 prolin; 4717 serin; 1507 tyrosin; 1306 trihydrÁt natrium-acetÁtu; 3008 hydrogenfosforeČnan draselnÝ; 1322 chlorid sodnÝ; 856 hexahydrÁt chloridu hoŘeČnatÉho; 4957 monohydrÁt glukosy; 5599 dihydrÁt chloridu vÁpenatÉho - infuzní roztok - roztoky pro parenterÁlnÍ vÝŽivu, kombinace